ClinicalTrials.gg
CompletedNCT06125691Updated Oct 3, 2025

Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

A Phase 1 interventional study of ARCT-2138 and Licensed Quadrivalent Vaccine for younger adults in Influenza, Human, sponsored by Arcturus Therapeutics, Inc.. Completed at 2 sites in Australia. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by Arcturus Therapeutics, Inc. · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Influenza, Human with a site in Australia — 8 open to participants now, 12 under way, 3 of them phase 3. Influenza, Human · Australia.

Enrollment
62nd of 87
139 · median 360
Started
2024
with 4 others
Phase 1
20 of 99
3 open now
Registered
86th of 99
by date

Among the 99 studies in Influenza, Human with a site in Australia, this one is the 62nd largest by enrollment of the 87 interventional ones that give a count, is one of 5 that started in 2024, is one of 20 in phase 1, and was the 86th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

8 of the 99 studies in Influenza, Human with a site in Australia are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Influenza, Human with a site in Australia, or all of them as a file.
02

Study summary

This is a safety and Immunogenicity first-in-human dose-ranging study of self-amplifying RNA Seasonal Influenza Vaccine (ARCT-2138) in adults.

Read the detailed description

Phase 1, first-in-human, randomized, controlled, observer blind (open label Part 4 only), dose-escalation study, to assess the safety, tolerability, and immunogenicity of different dose levels of the ARCT-2138 vaccine, administered as a single dose to healthy young and older adults, in comparison with an inactivated influenza vaccine.

Study drug (ARCT-2138 or control) will be administered as an intramuscular (IM) injection. The study comprises of four parts. In Part 1, escalating dose levels of ARCT-2138 given as a single injection to younger adults will be evaluated sequentially.

Low, medium, and high dose levels of ARCT-2138 (as recommended by DSMB) will be further evaluated in younger adults in Part 2. Part 3 will evaluate low, medium, and high dose levels of ARCT-2138 (as recommended by DSMB) in older adults.

Part 4 (dose expansion phase) will administer a lower dose of ARCT-2138 in young adults.

Investigational Vaccine: ARCT-2138 (Part 1-3 only, no control vaccine for Part 4) Control Vaccines: licensed influenza vaccines (inactivated)

  • For younger adults: Flucelvax® Quad, Seqirus Pty Ltd.
  • For older adults: Fluad® Quad, Seqirus Pty Ltd.
03

Conditions studied

  • Influenza, Human

Browse trials for

Keywords

  • Influenza
  • Vaccine
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals are male, female, or transgender adults 18 to 49 years of age or 65 to 85 years of age.
  2. Healthy participants or participants with pre-existing stable medical conditions. Pre-existing stable medical condition means a subject who: has full capacity of daily activity and no major medication modification; has not undergone surgical or minimally invasive intervention or had any hospitalization/emergency room visit for the specific medical condition within 3 months prior to Day 1.
  3. Participant or legally authorized representatives must freely provide documented prior to study procedures being performed.
  4. Individuals who have not received influenza vaccine within 6 months prior to enrollment.
  5. Individuals must agree to comply with all study visits and procedures (including blood tests, nasopharyngeal swabs, diary completion, receipt of telephone calls from the site, willingness to be available for Unscheduled Clinic Visits).
  6. Individuals of must be willing to adhere to requirements.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with acute medical illness or febrile illness, including body temperature >100.4°F (>38.0°C) within 3 days prior to Randomization. These individuals may be offered the opportunity to enter the study after fever and illness has stabilized. Participants with suspected or confirmed influenza should be excluded and referred for medical care. Rescreening will be permitted for individuals who are presented with suspected influenza if another diagnosis is confirmed.
  2. Individuals with any medical, neurological, or psychiatric condition that, in the opinion of the investigator, could place the participant at an unacceptable risk of injury or render the participant unable to comply with all study procedures and achieve successful completion of the trial.
  3. Individuals with a known history of severe reactions, including anaphylaxis, or other significant adverse reactions to any mRNA vaccine, influenza vaccine, or .
  4. Individuals who have a positive pregnancy test at the Screening visit or Day 1 or who intend to become pregnant or breastfeed during the study.
  5. Individuals with a history of myocarditis, pericarditis, myopericarditis or cardiomyopathy.
  6. Individuals with a history of Guillain-Barré syndrome, encephalomyelitis, or transverse myelitis.
  7. Individuals with a known bleeding disorder that would, in the opinion of the investigator, contraindicate intramuscular (I.M.) injection.
  8. Individuals with a history of congenital or acquired immunodeficiency.
  9. Individuals who have received immunomodulatory, immunostimulatory, or drugs including interferon and cytotoxic drugs within 3 months of Screening/Day 1 or who plan to receive them during the study.
  10. Individuals requiring systemic exceeding 10 mg/day of prednisone equivalent for ≥10 days within 30 days of Screening. The use of topical, ophthalmic, inhaled, and intranasal steroid preparations will be permitted.
  11. Individuals who have received immunoglobulins and/or any blood or blood products within the 3 months before the first vaccine administration or plan to receive such products at any time during the study.
  12. Individuals with an immunosuppressive or immunodeficient state, asplenia, or recurrent severe infections.
  13. Individuals with a documented history of chronic infection including , , , or who are currently known to have active tuberculosis.
  14. Individuals with chronic illness that, in the opinion of the Investigator, are at a stage where it might interfere with trial participation or interpretation of study results.
  15. Individuals receiving treatment with another drug, biological agent, or device within 28 days of screening, or 5 half-lives of the investigational drug, whichever is longer; or are currently enrolled in or plan to participate in another clinical trial with an investigational agent during the study period.
  16. Individuals who received any influenza vaccine within 6 months prior to enrollment. Individuals who plan to receive an influenza vaccine during the study period*.
  17. Individuals who have received any other licensed vaccines within 14 days prior to enrollment in this study or who are planning to receive any vaccine up to 14 days after the study vaccination.
  18. Individuals who are investigator site staff members, employees of the Sponsor or the Clinical Research Organization directly involved in the conduct of the study, or site staff members otherwise supervised by the investigator or immediate family members of any of the previously mentioned individuals.

    • Participants in the older adult group (Part 3) are allowed, following their Day 29 visit, to receive the authorized influenza vaccine as per country-specific recommendations.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Cohort 1 of ARCT-2138, younger adults

    Dose Level 1 of ARCT-2138 administered through intramuscular injection in the deltoid muscle. Interventions: Investigational Vaccine: ARCT-2138

    Biological: ARCT-2138

  • Experimental
    Cohort 2 of ARCT-2138, younger adults

    Dose Level 2 of ARCT-2138 administered through intramuscular injection in the deltoid muscle. Interventions: Investigational Vaccine: ARCT-2138

    Biological: ARCT-2138

  • Experimental
    Cohort 3 of ARCT-2138, younger adults

    Dose Level 3 of ARCT-2138 administered through intramuscular injection in the deltoid muscle. Interventions: Investigational Vaccine: ARCT-2138

    Biological: ARCT-2138

  • Experimental
    Cohort 4 of ARCT-2138, younger adults

    Dose Level 4 of ARCT-2138 administered through intramuscular injection in the deltoid muscle. Interventions: Investigational Vaccine: ARCT-2138

    Biological: ARCT-2138

  • Experimental
    Low Dose, younger and older adults

    Low dose level of ARCT-2138 administered through intramuscular injection in the deltoid muscle. Interventions: Investigational Vaccine: ARCT-2138

    Biological: ARCT-2138

  • Experimental
    Medium Dose, younger and older adults

    Medium dose level of ARCT-2138 administered through intramuscular injection in the deltoid muscle. Interventions: Investigational Vaccine: ARCT-2138

    Biological: ARCT-2138

  • Experimental
    High Dose, younger and older adults

    High dose level of ARCT-2138 administered through intramuscular injection in the deltoid muscle. Interventions: Investigational Vaccine: ARCT-2138

    Biological: ARCT-2138

  • Active comparator
    Control Dose, younger adults

    Licensed Quadrivalent Vaccine administered through intramuscular injection in the deltoid muscle. Interventions: Control Vaccine: Licensed Quadrivalent Vaccine for younger adults

    Biological: Licensed Quadrivalent Vaccine for younger adults

  • Active comparator
    Control Dose, older adults

    Licensed Quadrivalent Vaccine administered through intramuscular injection in the deltoid muscle. Interventions: Control Vaccine: Licensed Quadrivalent Vaccine for older adults

    Biological: Licensed Quadrivalent Vaccine for older adults

Interventions

  • BiologicalARCT-2138

    Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.

    Also known as: Self-Amplifying RNA seasonal Influenza vaccine

  • BiologicalLicensed Quadrivalent Vaccine for younger adults

    Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.

    Also known as: Influenza vaccine, surface antigen, inactivated, prepared in cell cultures

  • BiologicalLicensed Quadrivalent Vaccine for older adults

    Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.

    Also known as: Influenza vaccine, surface antigen, inactivated, adjuvanted

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting local Adverse Events

    Solicited local AEs include injection-site pain, erythema and swelling

    Time frame: 14 Days following study vaccination

  2. Percentage of participants reporting systemic Adverse Events

    Solicited systemic AEs include fatigue, headache, myalgia, arthralgia, nausea, chills, and fever.

    Time frame: 14 Days following study vaccination

  3. Percentage of participants reporting unsolicited Adverse Events

    Spontaneously reported adverse events and as elicited by investigational site staff

    Time frame: 29 Days following study vaccination

  4. Percentage of participants reporting laboratory or vital signs abnormalities

    Abnormal clinically significant values

    Time frame: 29 Days following study vaccination

  5. Percentage of participants reporting serious adverse events, medically attended adverse events adverse events of special interest and adverse events leading early termination

    Spontaneously reported adverse events and as elicited by investigational site staff

    Time frame: 29 Days following study vaccination

  6. Serum hemagglutination inhibition (HAI) antibody levels against the HA glycoprotein.

    HAI antibody levels expressed as GMT, GMFI, SCRs and HAI titers.

    Time frame: 29 days following study vaccination

  7. Serum neuraminidase enzyme-linked lectin (ELLA) assay antibody levels against the NA glycoproteins.

    ELLA antibody levels expressed as GMT, GMFI, SCRs and HAI titers.

    Time frame: 29 days following study vaccination

Secondary outcomes

  1. Percentage of participants reporting serious adverse events, medically attended adverse events adverse events of special interest and adverse events leading early termination

    Spontaneously reported adverse events and as elicited by investigational site staff

    Time frame: 181 days following study vaccination

  2. Serum hemagglutination inhibition (HAI) antibody levels against the HA glycoprotein.

    HAI antibody levels expressed as GMT, GMFI, SCRs and HAI titers.

    Time frame: 181 days following study vaccination

  3. Serum neuraminidase enzyme-linked lectin (ELLA) assay antibody levels against the NA glycoproteins.

    ELLA antibody levels expressed as GMT, GMFI, SCRs and HAI titers.

    Time frame: 181 days following study vaccination

07

Study locations

2 sites
  • Nucleus Network Brisbane Clinic
    Brisbane, Queensland, Australia
  • Emeritus Research Camberwell
    Melbourne, Victoria 3124, Australia
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will only be made available to study investigators at this time.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Aug 2024, 6 months.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 6 months is below that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2023
First posted
Nov 9, 2023
StartActual
Jan 22, 2024
Primary completionActual
Aug 10, 2024
CompletionActual
Jan 7, 2025
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06125691
Lead sponsor
Arcturus Therapeutics, Inc.
Collaborators
Seqirus, Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
Nov 9, 2023
Start date
Jan 22, 2024
Primary completion
Aug 10, 2024
Completion
Jan 7, 2025
Last update
Oct 3, 2025

Study contacts

Clinical Program Director
study director · Arcturus Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion